DNA-Topoisomerase I, a new target for the treatment of neuroblastoma

This publication has 11 references indexed in Scilit:

• Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts
  British Journal of Cancer, 1996
• Drug Evaluation: Oncologic, Endocrine & Metabolic: Irinotecan (CPT-11): Current status and perspectives
  Expert Opinion on Investigational Drugs, 1996
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
  Cancer Chemotherapy and Pharmacology, 1995
• Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials
  JNCI Journal of the National Cancer Institute, 1994
• Effects of CPT‐11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno‐transplanted neuroblastoma
  Medical and Pediatric Oncology, 1994
• Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
  Cancer Chemotherapy and Pharmacology, 1994
• DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
  Science, 1989
• Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835
  International Journal of Cancer, 1989
• Preclinical phase II studies in human tumor lines: A European multicenter study
  European Journal of Cancer and Clinical Oncology, 1988
• Proposal for the Application of Xenografts in Screening for New Anticancer Agents and in Selecting Tumor Types for Phase II Clinical Trials
  Published by Springer Nature ,1988